牡丹江医科大学学报

参考文献

[1]STIEG D C,WANG Y,LIU L Z,et al.ROS and miRNA Dysregulation in Ovarian Cancer Development,Angiogenesis and Therapeutic Resistance[J].Int J Mol Sci,2022,23(12):6702.

[2]DAHIYA N,MORIN P J.MicroRNAs in ovarian carcinomas[J].Endocr Relat Cancer,2010,17(1):77-89.

[3]WU B,ZHANG L,YU Y,et al.miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis[J].Cell Death Dis,2020,11(5):345.

[4]WU Z,GUO J,ZHANG Y,et al.MiR-425-5p accelerated the proliferation,migration and invasion of ovarian cancer cells via targeting AFF4[J].J Ovarian Res,2021,14(1):138.

[5]TUNG C H,KUO L W,HUANG M F,et al. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer[J].Oncogene,2020,39(4):862-876.

[6]徐玉红，张慧雅，王运根，等．微小RNA-128-3p通过调控锌指盒同源结合蛋白1抑制卵巢癌细胞上皮-间充质转化[J]．解剖学报，2022,53(6):762-768.

[7]CAO J,ZHANG Y,MU J,et al.Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6[J]. Hum Cell,2021,34(4):1185-1196.

[8]ZHENG Y,ZHU K,WANG G.miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6[J].Clin Exp Metastasis,2022,39(4):603-621.

[9]TUO X,ZHOU Y,YANG X,et al.miR-532-3p suppresses proliferation and invasion of ovarian cancer cells via GPNMB/HIF-1α/HK2 axis[J].Pathol Res Pract,2022(237):154032.

[10]SANCHEZ A M,FLAMINI M I,ZULLINO S,et al.Estrogen receptor-{alpha}promotes endothelial cell motility through focal adhesion kinase[J].Mol Hum Reprod,2011,17(4):219-226.

[11]LANGDON S P,HERRINGTON C S,HOLLIS R L,et al.Estrogen signaling and its potential as a target for therapy in ovarian cancer[J].Cancers(Basel),2020,12(6):1647.

[12]BOSCARO C,BAGGIO C,CAROTTI M,et al.Targeting of PFKFB3with miR-206 but not mir-26b inhibits ovarian cancer cell proliferation and migration involving FAK downregulation[J]. Faseb J,2022,36(3):22140.

[13]BOSCARO C,RAMASCHI G E,TREVISI L,et al.miR-206 inhibits estrogen signaling and ovarian cancer cell migration without affecting GPER[J].Life Sci,2023(333):122135.

[14]LIU J,XIAO Q,XIAO J,et al.Wnt/β-catenin signalling:function,biological mechanisms,and therapeutic opportunities[J]. Signal Transduct Target Ther,2022,7(1):3.

[15]WU X,ZHONG Y,ZHANG H,et al. miR-5590-3p inhibits the proliferation and invasion of ovarian cancer cells through mediating the Wnt/β-catenin signaling pathway by targeting TNIK[J].Histol Histopathol,2024,39(3):345-355.

[16]邵玉婷，彭浩，万淑琼，等．miRNA-5582在卵巢癌组织中的表达及对卵巢癌细胞增殖和侵袭的影响[J]．中国性科学，2024,33(6):60-65.

[17]LIU L J,SUN X Y,YANG C X,et al.MiR-10a-5p restrains the aggressive phenotypes of ovarian cancer cells by inhibiting HOXA1[J].Kaohsiung J Med Sci,2021,37(4):276-285.

[18]YU H Y,PAN S S.MiR-202-5p suppressed cell proliferation,migration and invasion in ovarian cancer via regulating HOXB2[J].Eur Rev Med Pharmacol Sci,2020,24(5):2256-2263.

[19]XUE W,YANG L,CHEN C,et al. Wnt/β-catenin-driven EMT regulation in human cancers[J]. Cell Mol Life Sci,2024,81(1):79.

[20]LIU L,NING Y,YI J,et al.miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression[J].Biomed Pharmacother,2020(125):109865.

[21]PENG Y,WANG Y,ZHOU C,et al.PI3K/Akt/m TOR Pathway and its role in cancer therapeutics:are we making headway?[J].Front Oncol,2022(12):819128.

[22]ZHANG Q,ZHOU X,WAN M,et al. Fox P3-miR-150-5p/3p suppresses ovarian tumorigenesis via an IGF1R/IRS1 pathway feedback loop[J].Cell Death Dis,2021,12(3):275.

[23]WANG X,JIANG L,LIU Q.miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation,migration,invasion,and chemotherapy resistance[J].J Transl Med,2022,20(1):258.

[24]WU H,LIU J,ZHANG Y,et al.miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway[J].Clin Transl Oncol,2021,23(2):257-264.

[25]JIANG H W,LI L,JIANG P,et al.MicroRNA-489 targets XIAP to inhibit the biological progression of ovarian cancer via regulating PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition[J].Eur Rev Med Pharmacol Sci,2020,24(8):4113-4122.